Takeda Pharma Ups Commitment to China
Takeda Pharma of Japan (TKPHF.PK), which bills itself as the largest pharma in Asia, has signed an agreement with China Medical City in Taizhou. The companys China subsidiary will build facilities in CMC, including buildings for R&D, manufacturing and marketing of innovative drugs.
The company candidly admits it is playing catch-up in China. We missed the boat several times in China, said Yasuchika Hasegawa, President of Takeda, last year. We are trying to catch the last boat.
Takeda invested $150 million Takeda China, and the press release also said the subsidiary would have registered capital of $50 million.
In its new-found commitment to China, Takeda pledged to send the best technology and talent to the PRC, according to Haruhiko Hirate, Chairman of the Asian Region for Takeda. However, he said the goal will be marketing to the entire populace of China and production of drugs there. He did not mention
Complete Story
Comments